{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:45:16Z","timestamp":1762033516882,"version":"3.37.3"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HD079918"],"award-info":[{"award-number":["HD079918"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,25]]},"DOI":"10.1093\/infdis\/jiy104","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T04:12:00Z","timestamp":1519791120000},"page":"1861-1864","source":"Crossref","is-referenced-by-count":6,"title":["Searching for a Serological Correlate of Protection for a CMV Vaccine"],"prefix":"10.1093","volume":"217","author":[{"given":"M R","family":"Schleiss","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases and Immunology, Department of Pediatrics, and Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota Medical School, Minneapolis"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"key\n\t\t\t\t20180626074844_CIT0001","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/JVI.64.3.1079-1085.1990","article-title":"Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response","volume":"64","author":"Britt","year":"1990","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180626074844_CIT0002","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/382751","article-title":"Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine","volume":"189","author":"Schleiss","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074844_CIT0003","doi-asserted-by":"crossref","first-page":"e00300-16","DOI":"10.1128\/CVI.00300-16","article-title":"Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B\/pp65 vaccination using a lymphocytic choriomeningitis virus vector","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20180626074844_CIT0004","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-016-0653-5","article-title":"Cytomegalovirus vaccines: current status and future prospects","volume":"76","author":"Anderholm","year":"2016","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180626074844_CIT0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.virol.2012.09.024","article-title":"HCMV gB shares structural and functional properties with gB proteins from other herpesviruses","volume":"435","author":"Sharma","year":"2013","journal-title":"Virology"},{"key":"key\n\t\t\t\t20180626074844_CIT0006","doi-asserted-by":"crossref","first-page":"e1005227","DOI":"10.1371\/journal.ppat.1005227","article-title":"Crystal structure of the human cytomegalovirus glycoprotein B","volume":"11","author":"Burke","year":"2015","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20180626074844_CIT0007","first-page":"90","article-title":"A recombinant subunit vaccine approach to HCMV vaccine development","volume":"23","author":"Spaete","year":"1991","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20180626074844_CIT0008","doi-asserted-by":"crossref","first-page":"e00268-17","DOI":"10.1128\/CVI.00268-17","article-title":"Progress toward development of a vaccine against congenital cytomegalovirus infection","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20180626074844_CIT0009","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/QCO.0000000000000409","article-title":"Viral infections in solid organ transplant recipients: novel updates and a review of the classics","volume":"30","author":"Haidar","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t20180626074844_CIT0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hemonc.2017.05.001","article-title":"Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation","volume":"10","author":"Camargo","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"key\n\t\t\t\t20180626074844_CIT0011","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626074844_CIT0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180626074844_CIT0013","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626074844_CIT0014","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy102","article-title":"Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: anti-AD2 levels correlate with protection from viremia","author":"Baraniak","year":"2018","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074844_CIT0015","doi-asserted-by":"crossref","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"P\u00f6tzsch","year":"2011","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20180626074844_CIT0016","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/MMBR.00018-16","article-title":"Virion glycoprotein-mediated immune evasion by human cytomegalovirus: a sticky virus makes a slick getaway","volume":"80","author":"Gardner","year":"2016","journal-title":"Microbiol Mol Biol Rev"},{"key":"key\n\t\t\t\t20180626074844_CIT0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2014.03.015","article-title":"A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign","volume":"60","author":"Ohlin","year":"2014","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20180626074844_CIT0018","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/emboj.2008.179","article-title":"Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus","volume":"27","author":"Thomson","year":"2008","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t20180626074844_CIT0019","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1080\/21645515.2016.1164376","article-title":"Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus","volume":"12","author":"Finnefrock","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180626074844_CIT0020","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/AAC.04295-14","article-title":"A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types","volume":"59","author":"Kauvar","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"article-title":"ClinicalTrials.gov. Theraclone Sciences, Inc. Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody","year":"2014","author":"US National Library of Medicine","key":"key\n\t\t\t\t20180626074844_CIT0021"},{"journal-title":"J Virol","article-title":"Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections","author":"Permar","key":"key\n\t\t\t\t20180626074844_CIT0022"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/217\/12\/1861\/25090309\/jiy104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T20:20:01Z","timestamp":1603916401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/217\/12\/1861\/4924674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,3,8]]},"published-print":{"date-parts":[[2018,5,25]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy104","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2018,6,15]]},"published":{"date-parts":[[2018,3,8]]}}}